Content area
Full Text
Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma. The French Big Pharma is paying $40 million upfront to pick up the preclinical asset, with $765 million more to follow if it passes all the milestones that await.
Principia has taken BTK inhibitor PRN2246 up to and into IND-enabling studies. Along the way, the biotech has generated data suggesting the drug triggers the effects on immune cell signaling that have made BTK inhibitors hot property in the autoimmune space. Crucially, Principia...